Scholarlink

Introduction <p>Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is indicated for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). This study aims to evaluate the efficacy and safety profiles of solriamfetol across different severity levels of OSA via the post hoc analysis of a randomized clinical trial in a Chinese population.</p> Methods <p>Participants were assigned in a 1:1 ratio to either the placebo group or solriamfetol group (dose titrated up to 150&#xa0;mg/day) for 12 consecutive weeks, with randomization stratified by adherence status to primary OSA therapy. The co-primary endpoints were defined as the changes of mean sleep latency measured by the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) scores from baseline to week&#xa0;12 in the full analysis set. The efficacy and safety profiles of solriamfetol were analyzed across subgroups stratified by baseline apnea hypopnea index (AHI).</p> Results <p>Among eligible patients for subgroup analysis, 42.5%, 34.5%, and 23% had baseline AHI &lt; 5, 5 ≤ AHI &lt; 30, and AHI ≥ 30, respectively. At week&#xa0;12, solriamfetol treatment significantly prolonged MWT sleep latency relative to placebo across all AHI subgroups. The least squares (LS) mean differences (standard error) versus placebo were 12.133 (2.2239)&#xa0;min for the AHI &lt; 5 subgroup (<i>P</i> &lt; 0.0001), 12.676 (2.5363)&#xa0;min for the 5 ≤ AHI &lt; 30 subgroup (<i>P</i> &lt; 0.0001), and 10.935 (2.6023)&#xa0;min for the AHI ≥ 30 subgroup (<i>P</i> = 0.0001). In subgroups with baseline AHI &lt; 5 and 5 ≤ AHI &lt; 30, solriamfetol significantly reduced ESS scores vs. placebo (LS mean difference [SE] versus placebo, −&#xa0;2.0 [0.95] and −&#xa0;2.1 [1.01], <i>P</i> = 0.0404 and <i>P</i> = 0.0394, respectively). In the baseline AHI ≥ 30 subgroup, solriamfetol showed a tendency toward reduction in ESS scores compared with placebo, although the difference was not statistically significant (<i>P</i> = 0.2497). Meanwhile, solriamfetol was well tolerated, with the most common treatment-emergent adverse events (&gt; 10% incidence in any treatment group) including upper respiratory tract infection, hyperuricemia, dizziness, and hypertension.</p> Conclusion <p>Solriamfetol showed good efficacy and tolerability regardless of OSA severity among Chinese OSA participants with EDS.</p> Trial Registration <p>The parent study was registered at <a href="http://www.chinadrugtrials.org.cn">www.chinadrugtrials.org.cn</a> with the trial number CTR20231397 on May&#xa0;15, 2023.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Post Hoc Analysis of Solriamfetol Efficacy in Obstructive Sleep Apnea Patients with Excessive Daytime Sleepiness Stratified by Disease Severity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Changjun Su,
  • Jiucheng Shen,
  • Kaida Guo,
  • Jing Wang,
  • Zhijun Wang,
  • Shiyuan Gao,
  • Qiaojun Wang,
  • Fei Han,
  • Weijia Zhang,
  • Hui Ye,
  • Xiang Li,
  • Ruolin Zhang,
  • Rui Chen

摘要

Introduction

Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is indicated for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). This study aims to evaluate the efficacy and safety profiles of solriamfetol across different severity levels of OSA via the post hoc analysis of a randomized clinical trial in a Chinese population.

Methods

Participants were assigned in a 1:1 ratio to either the placebo group or solriamfetol group (dose titrated up to 150 mg/day) for 12 consecutive weeks, with randomization stratified by adherence status to primary OSA therapy. The co-primary endpoints were defined as the changes of mean sleep latency measured by the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) scores from baseline to week 12 in the full analysis set. The efficacy and safety profiles of solriamfetol were analyzed across subgroups stratified by baseline apnea hypopnea index (AHI).

Results

Among eligible patients for subgroup analysis, 42.5%, 34.5%, and 23% had baseline AHI < 5, 5 ≤ AHI < 30, and AHI ≥ 30, respectively. At week 12, solriamfetol treatment significantly prolonged MWT sleep latency relative to placebo across all AHI subgroups. The least squares (LS) mean differences (standard error) versus placebo were 12.133 (2.2239) min for the AHI < 5 subgroup (P < 0.0001), 12.676 (2.5363) min for the 5 ≤ AHI < 30 subgroup (P < 0.0001), and 10.935 (2.6023) min for the AHI ≥ 30 subgroup (P = 0.0001). In subgroups with baseline AHI < 5 and 5 ≤ AHI < 30, solriamfetol significantly reduced ESS scores vs. placebo (LS mean difference [SE] versus placebo, − 2.0 [0.95] and − 2.1 [1.01], P = 0.0404 and P = 0.0394, respectively). In the baseline AHI ≥ 30 subgroup, solriamfetol showed a tendency toward reduction in ESS scores compared with placebo, although the difference was not statistically significant (P = 0.2497). Meanwhile, solriamfetol was well tolerated, with the most common treatment-emergent adverse events (> 10% incidence in any treatment group) including upper respiratory tract infection, hyperuricemia, dizziness, and hypertension.

Conclusion

Solriamfetol showed good efficacy and tolerability regardless of OSA severity among Chinese OSA participants with EDS.

Trial Registration

The parent study was registered at www.chinadrugtrials.org.cn with the trial number CTR20231397 on May 15, 2023.